Effect of Amiodarone After Ischemic Ventricular Tachycardia Ablation
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Ischemic Cardiomyopathy
- Sponsor
- Yuksek Ihtisas Hospital
- Enrollment
- 100
- Locations
- 1
- Primary Endpoint
- Major adverse cardiovascular events
- Last Updated
- 8 years ago
Overview
Brief Summary
Ventricular Tachycardia ablation in ischemic cardiomyopathy patients is required procedure in cases when anti-arrhythmic drugs failed. The concern is if adjunctive continuation amiodarone after ablation is needed.
Detailed Description
Ischemic cardiomyopathy patients have implantable cardioverter defibrillators (ICD) to prevent arrhythmic deaths. Ventricular tachycardia (VT) events with frequent ICD interventions in ischemic cardiomyopathy patients is encountered frequently. Frequents ICD interventions is associated with worse outcomes. Anti-arrhythmic drugs ,mostly amiodarone, are given prevent ventricular arrhythmias and ICD interventions that may not be curative. Ablation of ventricular tachycardia is the suggested treatment when anti-drugs are without effect. After ablation of ventricular arrhythmia the continuation of amiodarone is not well elucidated. In this study we aimed to enroll ischemic cardiomyopathy patients having frequent ICD interventions despite medical treatment. VT ablation is performed and patients divided into two groups; group one continues having amiodarone after ablation, group two does not have amiodarone after ablation. Both groups will be compared in terms of recurrence and death.
Investigators
Fırat Özcan
Associate Professor
Yuksek Ihtisas Hospital
Eligibility Criteria
Inclusion Criteria
- •Ischemic cardiomyopathy patients applied with frequent ICD interventionor electrical storms and having ejection fraction below 50%. Frequent ICD defined as more than 1 ICD intervention within month. Electrical storm defined as more than 2 ICD intervention within one day.
Exclusion Criteria
- •Patients with cardiomyopathies other than ischemic etiology
Outcomes
Primary Outcomes
Major adverse cardiovascular events
Time Frame: six months
Death, ICD intervetion